Sigilon Therapeutics
Andrew Torres is an Associate Scientist at Sigilon Therapeutics, specializing in media formulation for stem cell culture and sterile filtration. Previous experience includes roles as Associate Scientist II and I at 2seventy bio, where responsibilities encompassed vector process development and downstream processing. Previous positions include bioprocessing lab technician at Motif FoodWorks, Inc., R&D Intern at Eutropics focusing on cell culture for antibody production, and laboratory technician at Boston Children's Hospital, with a focus on coagulation lab analyses. Andrew holds a Master of Science in Molecular Biotechnology and a Bachelor of Science in Biotechnology from Northeastern University, as well as an Associate's degree from Quincy College in Biotechnology and GMP.
Sigilon Therapeutics
2 followers
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.